EGFR and non-small cell lung carcinoma: Kinases involved in the resistance to EGFR inhibitors have been extensively studied in NSCLC and lung adenocarcinomas, revealing many kinases that contribute to a resistant phenotype, including c-Met, HER2, HER3, VEGFR, PDGFR, PI3K, AKT, FAK, JAK, and ERK [45,48].